References
- 1Makuc J. Management of pancreatogenic diabetes: challenges and solutions. Diabetes Metab Syndr Obes. 2016; 9: 311–315. Published 2016 Aug 25. DOI: 10.2147/DMSO.S99701
- 2Hart PA, Bellin MD, Andersen DK, et al. Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. Lancet Gastroenterol Hepatol. 2016; 1(3): 226–237. DOI: 10.1016/S2468-1253(16)30106-6
- 3Ewald N, Bretzel RG. Diabetes mellitus secondary to pancreatic diseases (Type 3c) – are we neglecting an important disease? Eur J Intern Med. 2013; 24(3): 203–206. DOI: 10.1016/j.ejim.2012.12.017
- 4Chua CB, Sun CK, Hsu CW, Tai YC, Liang CY, Tsai IT. “Diabetic striatopathy”: clinical presentations, controversy, pathogenesis, treatments, and outcomes. Sci Rep. 2020; 10: 1594. DOI: 10.1038/s41598-020-58555-w
- 5Chatterjee S, Ghosh R, Kumari R, Ojha UK, Benito-León J, Dubey S. Faciobrachial Myoclonus as the Presenting Manifestation of Diabetic Keto-Acidosis. Tremor Other Hyperkinet Mov (N Y). 2021; 11:
9 . Published 2021 Mar 2. DOI: 10.5334/tohm.605 - 6Mathew J, Mohan M, Menon A. Multiple Cranial Neuropathies in a Patient with Diabetes Mellitus. Ann Indian Acad Neurol. 2019; 22(3): 353–355. DOI: 10.4103/aian.AIAN_402_18
- 7Kelkar P, Parry GJ. Mononeuritis multiplex in diabetes mellitus: Evidence for underlying immune pathogenesis. J Neurol Neurosurg Psychiatry. 2003; 74: 803–6. DOI: 10.1136/jnnp.74.6.803